Global Gene Therapy for Inherited Genetic Disorders Market 2019-2023 | Increasing Strategic Alliances to Boost Growth | Technavio
LONDON--(BUSINESS WIRE)--May 27, 2019--
The global gene therapy for inherited genetic disorders market is expected to post a CAGR of about 189% during the period 2019-2023, according to the latest market research report by Technavio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190527005118/en/
Technavio has published a new market research report on the global gene therapy for inherited genetic disorders market from 2019-2023. (Graphic: Business Wire)
A key factor driving the global gene therapy for inherited genetic disorders market growth is the high efficacy and safety of gene therapies. This technology has the potential of curing inherited diseases that are treatable but not curable with other conventional drugs. Gene therapies are gaining momentum in clinical trials and showing promising results with optimum efficacy and safety to treat inherited genetic disorders. Market players are introducing gene therapy solutions for inherited genetic disorders such as spinal muscular atrophy and ADA-severe combined immunodeficiency. The high efficacy and safety offered by modern gene therapies will boost the gene therapy for inherited genetic disorders market during the forecast period.
As per Technavio’s gene therapy for inherited genetic disorders market analysis, the increase in strategic alliances will have a positive impact on the market and contribute to its growth significantly over the forecast period. This global gene therapy for inherited genetic disorders market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.
Global gene therapy for inherited genetic disorders market: Increase in strategic alliances
Several vendors are entering the market to form strategic alliances with medium enterprises and conglomerate companies. Furthermore, the manufacture of high-quality plasmid and viral vectors is one of the critical components required for the commercialization of cell and gene therapy. As a result, various market players are increasingly engaging in forming strategic collaborations to focus on developing novel approaches for the treatment of several inherited genetic disorders.
“Market players are focusing on extensive collaborations to develop long-term treatment therapies for patients with cystic fibrosis. Also, market participants are also engaging in strategic partnerships to manufacture platforms for future gene therapy programs, including the limb-girdle muscular dystrophy. Such developments and collaborations will lead to the growth of the market,” says a senior research analyst at Technavio.
Global gene therapy for inherited genetic disorders market: Segmentation analysis
This gene therapy for inherited genetic disorders market outlook segments the global gene therapy for inherited genetic disorders market by application (eye-disorders, hematological disorders, central nervous system disorders, muscular disorders, and others) and geographic regions (North America, Europe, Asia, and ROW).
North America led the market in 2018, followed by Europe, Asia, and ROW, respectively. The market growth in North America can be attributed to the growing prevalence of inherited genetic disorders, including sickle cell anemia and spinal muscular atrophy in the US.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Five Forces Analysis
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190527005118/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS
SOURCE: Technavio Research
Copyright Business Wire 2019.
PUB: 05/27/2019 08:30 AM/DISC: 05/27/2019 08:30 AM